Drugs in R & D

, Volume 5, Issue 6, pp 351–354 | Cite as


AMJ 9701, KGF — Amgen, Recombinant Human Keratinocyte Growth Factor, rHu-KGF
Adis R&D Profile


Lipase Placebo Recipient Metastatic Colorectal Cancer Oral Mucositis Serum Amylase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Durrant S, Pico JL, Schmitz N, et al. A phase I study of recombinant human keratinocyte growth factor in lymphoma patients receiving high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Blood 94 (Suppl. 1): 708, Part 1, 15 Nov 1999Google Scholar
  2. 2.
    Meropol NJ, Gutheil J, Pelley R, et al. Keratinocyte growth factor as a mucositis protectant: a randomized phase I trial. 36th Annual Meeting of the American Society of Clinical Oncology 19: 603, 20 May 2000Google Scholar
  3. 3.
    Amgen Inc. Phase 3 Data Show Palifermin Improves Patient Reported Outcomes in Cancer Patients and Helps Reduce Hospitalizations and Healthcare Resources. Media Release: 9 Dec 2003. Available from URL:
  4. 4.
    Amgen Inc. Phase 3 Data Suggest Palifermin Significantly Reduces the Duration and Incidence of Oral Mucositis in Cancer Patients. Media Release: 1 Jun 2003. Available from URL: Google Scholar
  5. 5.
    Panoskaltsis-Mortari A, Lacey DL, Vallera DA. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92: 3960–3967, 15 Nov 1998PubMedGoogle Scholar
  6. 6.
    Amgen. Amgen’s KGF shows preliminary efficacy in preventing chemotherapy-induced severe oral mucositis. Media Release [4 pages]: 14 May 2001. Available from URL:
  7. 7.
    Amgen. Amgen Announces Positive Results of Phase 3 Study for rHu-KGF. Media Release: 23 Jan 2003. Available from URL:
  8. 8.
    Stiff P, Bensinger W, Emmanouilides C, et al. Treatment of mucositis with palifermin improves patient function and results in a clinically meaningful reduction in mouth and throat soreness: phase 3 results. Blood 102: 194, No. 11, Part 1, 16 Nov 2003Google Scholar
  9. 9.
    Emmanouilides C, Spielberger R, Stiff P, et al. Palifermin treatment of mucositis in transplant patients reduces health resource use: phase 3 results. Blood 102: 251–252, No. 11, Part 1, 16 Nov 2003Google Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations